About Amarantus Bioscience Holdings (OTCBB:AMBS)
Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The companys diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimers disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinsons disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinsons disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus Bioscience Holdings, Inc. in April 2013. Amarantus Bioscience Holdings, Inc. was founded in 2008 and is based in San Francisco, California.
Industry, Sector and Symbol:
- Industry: Biotechnology
- Sub-Industry: N/A
- Sector: Healthcare
- Symbol: OTCBB:AMBS
- CUSIP: N/A
- Web: www.amarantus.com
Frequently Asked Questions for Amarantus Bioscience Holdings (OTCBB:AMBS)
What is Amarantus Bioscience Holdings' stock symbol?
Amarantus Bioscience Holdings trades on the OTCBB under the ticker symbol "AMBS."
How were Amarantus Bioscience Holdings' earnings last quarter?
Amarantus Bioscience Holdings, Inc (OTCBB:AMBS) posted its quarterly earnings results on Monday, November, 23rd. The company reported ($0.98) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.77) by $0.21. View Amarantus Bioscience Holdings' Earnings History.
Who are some of Amarantus Bioscience Holdings' key competitors?
Some companies that are related to Amarantus Bioscience Holdings include CSL Limited (CSL), Jazz Pharmaceuticals PLC (JAZZ), Grifols, S.A. (GRFS), ProMetic Life Sciences (PLI), Sirtex Medical Limited (SRX), Theratechnologies (TH), Mirati Therapeutics (MRTX), OrganiGram Holdings (OGI), Siga Technologies (SIGA), VBI Vaccines (VBIV), Osiris Therapeutics (OSIR), XOMA Corporation (XOMA), Anavex Life Sciences Corp. (AVXL), Trillium Therapeutics (TRIL), Aevi Genomic Medicine (GNMX), ContraFect Corporation (CFRX), Concordia International Corp. (CXR) and Soligenix (SNGX).
How do I buy Amarantus Bioscience Holdings stock?
Shares of Amarantus Bioscience Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
MarketBeat Community Rating for Amarantus Bioscience Holdings (OTCBB AMBS)MarketBeat's community ratings are surveys of what our community members think about Amarantus Bioscience Holdings and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Amarantus Bioscience Holdings (OTCBB:AMBS) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 0 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Hold (Score: 2.00)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Amarantus Bioscience Holdings (OTCBB:AMBS)
Analysts' Ratings History for Amarantus Bioscience Holdings (OTCBB:AMBS)
(Data available from 11/21/2015 forward)
|12/7/2016||WallachBeth Capital||Downgrade||Buy -> Hold|
Earnings History and Estimates Chart for Amarantus Bioscience Holdings (OTCBB:AMBS)
Earnings History by Quarter for Amarantus Bioscience Holdings (OTCBB AMBS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Amarantus Bioscience Holdings (OTCBB:AMBS)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Amarantus Bioscience Holdings (OTCBB:AMBS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Amarantus Bioscience Holdings (OTCBB AMBS)
Insider Trades by Quarter for Amarantus Bioscience Holdings (OTCBB AMBS)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/2/2015||Robert Lewis Harris||Director||Buy||19,500||$0.48||$9,360.00|| |
|4/9/2015||Robert Edward Farrell||CFO||Buy||200,000||$0.05||$10,000.00|| |
|4/8/2015||Gerald Commissiong||CEO||Buy||240,000||$0.05||$12,000.00|| |
|11/20/2014||Gerald Commissiong||CEO||Buy||130,000||$0.08||$10,400.00|| |
|11/19/2014||Robert Edward Farrell||CFO||Buy||133,333||$0.08||$10,666.64|| |
|1/17/2014||Gerald Commissiong||CEO||Buy||50,000||$0.09||$4,500.00|| |
|4/30/2013||Gerald Commissiong||CEO||Buy||50,000||$0.05||$2,500.00|| |
Latest Headlines for Amarantus Bioscience Holdings (OTCBB AMBS)
|Avant Diagnostics Highlights Published Clinical Utility Data for Theralink® mTOR Pathway Activation Data Predicting Tamoxifen® and Other Endocrine Treatment Response in Estrogen Receptor Positive (ER+) Breast Cancer|
finance.yahoo.com - July 18 at 5:19 PM
|Avant Diagnostics Acquires Exclusive Option to License Genetic Health Solution Technology Platform|
finance.yahoo.com - July 12 at 4:18 PM
|Avant Diagnostics Appoints Philippe Goix, PhD, MBA as President & CEO to Commercialize Proprietary Theralink® Tumor Biomarker Platform|
www.prnewswire.com - June 21 at 4:20 PM
|AMARANTUS BIOSCIENCE HOLDINGS, INC. Files SEC form 8-K, Other Events|
biz.yahoo.com - October 27 at 9:00 PM
|AMARANTUS BIOSCIENCE HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers|
biz.yahoo.com - July 8 at 4:11 PM
|AMARANTUS BIOSCIENCE HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report|
biz.yahoo.com - June 1 at 1:22 PM
|AMARANTUS BIOSCIENCE HOLDINGS, INC. Files SEC form 10-K, Annual Report|
biz.yahoo.com - May 16 at 4:14 PM
|AMARANTUS BIOSCIENCE HOLDINGS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Dir|
biz.yahoo.com - April 21 at 4:21 PM
Amarantus Bioscience Holdings (OTCBB AMBS) Chart for Tuesday, November, 21, 2017